434 results on '"Uharek, Lutz"'
Search Results
2. Epithelial barrier dysfunction as permissive pathomechanism in human intestinal graft-versus-host disease
3. Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach
4. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
5. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
6. Immunotherapy: opportunities, risks and future perspectives
7. Prospective evaluation of the SeptiFAST multiplex real‐time PCR assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an in‐house real‐time PCR method
8. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor‐risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
9. Association between low uric acid levels and acute graft-versus-host disease
10. Cellular Immunotherapy of Acute Leukemias After High Dose Chemotherapy with Cytarabin (ARA-C) and Cyclophosphamide (CY) in a Murine Model
11. The Influence of the Hematopoietic System on the Production of MHC-Related Odors in Mice
12. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
13. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study
14. Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation
15. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
16. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
17. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation
18. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease
19. Biocompatible porous ceramics for the cultivation of hematopoietic cells
20. A Novel Method to Quantify and Characterize Leukemia-Reactive Natural Killer Cells in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation following Conventional or Reduced-Dose Conditioning
21. Chronic Graft versus Host Disease but not the Intensity of Conditioning has Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Hematological Diseases
22. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
23. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation
24. Impairment of renal function in Schnitzlerʼs syndrome
25. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease
26. Air embolism simulating atypical pneumonia
27. Peripheral Blood Stem Cells for Allogeneic Transplantation
28. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony-stimulating factor and interleukin 2 in a myeloma model
29. Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma
30. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells
31. Cellular Immunotherapy of Acute Leukemias After High Dose Chemotherapy with Cytarabin (ARA-C) and Cyclophosphamide (CY) in a Murine Model
32. Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
33. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
34. Stellungnahme zur Nutzenbewertung gemäß § 35a SGB V eines Arzneimittels für seltene Leiden (Orphan Drug), veröffentlicht am 16. April 2018, Vorgangsnummer 2018-01-15-D-333, IQWiG Bericht Nr. 615
35. Automation: the Key Enabler of Point-of-Care Cell & Gene Therapy Manufacturing
36. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells
37. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
38. Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
39. Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients
40. Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
41. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
42. Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease
43. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial
44. Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections
45. Prospective evaluation of the Septi FAST multiplex real-time PCR assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an in-house real-time PCR method
46. Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
47. Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group
48. Minimum Tolerable Interval of Radioimmunotherapy and Autologous Stem Cell Transplantation after High-Dose Chemotherapy for Relapsed or Refractory Aggressive B Cell Non-Hodgkin-Lymphoma Provides Excellent Disease Control
49. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)
50. Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.